Harmony Biosciences Holdings Stock
Harmony Biosciences Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jeffrey Dayno
- Employees
- 293
- Market cap
- $2.2 B
- IPO
- 19/08/2020
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. The flagship product of the company is WAKIX, which is a prescription medication designed to treat excessive…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Harmony Biosciences Holdings stock: price history
1D
-0.8%
1W
-5.8%
1M
-10.1%
6M
+26.5%
YTD
+1.4%
1Y
+46.2%
2Y
+8.9%
5Y
-3.7%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~55% stronger price swings than usual
Harmony Biosciences Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. Its core business is based on the sale of its flagship product WAKIX, a prescription medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company operates exclusively in the US market and generates all of its revenues there. Since its founding in 2017, the company has specialized in serving patients with specific neurological indications.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Harmony Biosciences Holdings
Analyst assessment of Harmony Biosciences Holdings
PRICE TARGET LOW
US$34.00
CONSENSUS
US$49.00
MEDIAN
US$46.50
PRICE TARGET HIGH
US$70.00
0
STRONG BUY
8
BUY
3
HOLD
2
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 13/10/2026
Harmony Biosciences Holdings stock metrics
P/E
12.12
P/B
2.2
EV/EBITDA
6.56
RETURN ON EQUITY
7.5%
NET MARGIN
28.9%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.2%
FLOAT SHARES
50,196,981
AVG. DAILY VOLUME (30D)
1,024,032
Insider transactions (SEC)
Budur Kumar
Budur Kumar
Budur Kumar
Budur Kumar
Budur Kumar
Institutional holders
Comparable stocks
Frequently asked questions about Harmony Biosciences Holdings stock
What does Harmony Biosciences Holdings do?
Harmony Biosciences Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jeffrey Dayno, the company employs around 293 people.
The IPO was on 19/08/2020; the stock trades on NASDAQ under the ticker HRMY.
What do analysts say about Harmony Biosciences Holdings stock?
13 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$49.00, ranging from US$34.00 to US$70.00, with a median of US$46.50.
This is an external assessment, not a statement by Market Jury.
When does Harmony Biosciences Holdings report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 55% stronger than usual.
Does Harmony Biosciences Holdings pay a dividend?
No, Harmony Biosciences Holdings currently does not pay a dividend.
Which stocks are comparable to Harmony Biosciences Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Harmony Biosciences Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Harmony Biosciences Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.